DRUG: Trial of DMXB-A in Schizophrenia NCT00100165

After you have viewed the pdf on Clin" rel="nofollow">inical Study Design: DRUG: Trial of DMXB-A in" rel="nofollow">in Schizophrenia NCT00100165 INSTRUCTIONS: Summarize the drug, MOA, study design, with the in" rel="nofollow">inclusion and exclusion criteria. What percent of patients (approximately) of the total affected with this disease would be eligible to be treated? If the population studied in" rel="nofollow">in the trial are the only patients eligible for treatment when the drug is approved, what percent (approximately) would not be able to take this medication? Discuss the restrictions to the target population, and any other special circumstances for either in" rel="nofollow">includin" rel="nofollow">ing or excludin" rel="nofollow">ing sub groups of patients and in" rel="nofollow">include your rationale. 1-2 pages total. No more than 3-5 references are needed (primary publications only) Here are the comments I got on the first paper: “This paper has a lot of good in" rel="nofollow">information in" rel="nofollow">in it, but needs more editin" rel="nofollow">ing. Each paper appears to be summarized in" rel="nofollow">in a different paragraph. Instead, in" rel="nofollow">incorporatin" rel="nofollow">ing the in" rel="nofollow">information to explain" rel="nofollow">in what they in" rel="nofollow">investigators did well and what they could have improved upon would make this a much stronger paper. The assignment was for a Phase I trial. This is a phase III trial. There was a phase one dose fin" rel="nofollow">indin" rel="nofollow">ing trial in" rel="nofollow">in 97 patients. The articles chosen for references are also review articles, not the primary publication for the study. It is important to choose the primary publication which is written by the in" rel="nofollow">investigators who did the research and reviewed all of the study data. Review articles summarize and in" rel="nofollow">interpret the in" rel="nofollow">information in" rel="nofollow">in the primary publication, and do NOT have access to all the data, only summary data in" rel="nofollow">in tables. Review authors also have not seen the full protocol and you should not base your writin" rel="nofollow">ing on their opin" rel="nofollow">inions. I will grade your paper based on what you submitted. Describin" rel="nofollow">ing the consequence of F508del would have been a good way to start your paper-it leads to abnormal water and chloride levels, and impacts lung and sweat secretions. Over time, this leads to thick mucus and causes lung damage and in" rel="nofollow">increases the risk for lung in" rel="nofollow">infections.” So please make sure you don’t make those same mistakes